X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

COVID-19 Response: Supporting the frontline

By Stephen J. Ubl  |    March 30, 2020
Updated 7/13/2020 In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19, a disease caused by a novel strain of...   Read More

Guest post: Looking out for the invisibly vulnerable in the time of COVID-19

By Guest Contributor  |    March 26, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

America’s biopharmaceutical companies are working around the clock to beat coronavirus

By Holly Campbell  |    March 20, 2020
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment to finding solutions to prevent,...   Read More

Guest post: Takeda’s efforts to address COVID-19

By Guest Contributor  |    March 19, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest ...   Read More

ICYMI: America’s biopharmaceutical companies are taking on COVID-19

By Andrew Powaleny  |    March 16, 2020
The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial...   Read More

PhRMA submits comments on FDA’s proposed rule on drug importation

By Nicole Longo  |    March 10, 2020
Yesterday, PhRMA submitted comments in response to the Food and Drug Administration’s proposed rule, “Importation of Prescription Drugs.” As PhRMA President and CEO Stephen J. Ubl stated when the...   Read More

Nearly 400 cell and gene therapies in development to target a broad range of diseases

By Andrew Powaleny  |    March 10, 2020
In 2017, the U.S. approved its first cell and gene therapy, making the idea of altering a gene to cure or treat a disease a reality. As the increasing pace of R&D propels cell and gene therapy...   Read More

ICYMI: Continued biopharmaceutical action on COVID-19

By Andrew Powaleny  |    March 6, 2020
Updated 3/11/2020 This week, PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss the industry’s response to COVID-19, a...   Read More

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

By Holly Campbell  |    March 3, 2020
Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt  patients’ ability...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates